nodes	percent_of_prediction	percent_of_DWPC	metapath
Sorafenib—kidney cancer—liver cancer	0.385	1	CtDrD
Sorafenib—RAF1—liver cancer	0.146	0.438	CbGaD
Sorafenib—BRAF—liver cancer	0.101	0.304	CbGaD
Sorafenib—RALBP1—Doxorubicin—liver cancer	0.0934	0.739	CbGbCtD
Sorafenib—KDR—liver cancer	0.0858	0.258	CbGaD
Sorafenib—ABCC2—Doxorubicin—liver cancer	0.0098	0.0775	CbGbCtD
Sorafenib—ABCG2—Doxorubicin—liver cancer	0.00886	0.0701	CbGbCtD
Sorafenib—ABCC2—bile canaliculus—liver cancer	0.00716	0.232	CbGeAlD
Sorafenib—CYP2B6—Doxorubicin—liver cancer	0.00623	0.0493	CbGbCtD
Sorafenib—ABCB1—Doxorubicin—liver cancer	0.0032	0.0253	CbGbCtD
Sorafenib—CYP2D6—Doxorubicin—liver cancer	0.00301	0.0238	CbGbCtD
Sorafenib—ABCC2—bile duct—liver cancer	0.00224	0.0725	CbGeAlD
Sorafenib—FLT1—umbilical vein—liver cancer	0.00206	0.0667	CbGeAlD
Sorafenib—CYP3A4—Doxorubicin—liver cancer	0.00191	0.0151	CbGbCtD
Sorafenib—KDR—umbilical vein—liver cancer	0.00174	0.0564	CbGeAlD
Sorafenib—ABCC2—bile—liver cancer	0.00172	0.0557	CbGeAlD
Sorafenib—Regorafenib—RAF1—liver cancer	0.00109	0.325	CrCbGaD
Sorafenib—Radiation recall reaction (dermatologic)—Epirubicin—liver cancer	0.000884	0.034	CcSEcCtD
Sorafenib—Recall phenomenon—Epirubicin—liver cancer	0.000837	0.0322	CcSEcCtD
Sorafenib—Radiation recall reaction (dermatologic)—Doxorubicin—liver cancer	0.000818	0.0314	CcSEcCtD
Sorafenib—PDGFRA—gall bladder—liver cancer	0.000793	0.0257	CbGeAlD
Sorafenib—Recall phenomenon—Doxorubicin—liver cancer	0.000774	0.0297	CcSEcCtD
Sorafenib—Regorafenib—ABL1—liver cancer	0.000758	0.225	CrCbGaD
Sorafenib—Regorafenib—BRAF—liver cancer	0.000758	0.225	CrCbGaD
Sorafenib—FLT4—embryo—liver cancer	0.00069	0.0224	CbGeAlD
Sorafenib—Regorafenib—KDR—liver cancer	0.000644	0.191	CrCbGaD
Sorafenib—KIT—gall bladder—liver cancer	0.000634	0.0205	CbGeAlD
Sorafenib—PDGFRB—gall bladder—liver cancer	0.000619	0.0201	CbGeAlD
Sorafenib—RET—embryo—liver cancer	0.000609	0.0197	CbGeAlD
Sorafenib—Oral pain—Epirubicin—liver cancer	0.000556	0.0214	CcSEcCtD
Sorafenib—FLT1—embryo—liver cancer	0.000536	0.0174	CbGeAlD
Sorafenib—RAF1—embryo—liver cancer	0.000533	0.0173	CbGeAlD
Sorafenib—Oral pain—Doxorubicin—liver cancer	0.000515	0.0198	CcSEcCtD
Sorafenib—Peripheral sensory neuropathy—Epirubicin—liver cancer	0.000508	0.0195	CcSEcCtD
Sorafenib—PDGFRA—embryo—liver cancer	0.000503	0.0163	CbGeAlD
Sorafenib—CDK7—liver—liver cancer	0.000488	0.0158	CbGeAlD
Sorafenib—TAOK2—liver—liver cancer	0.000485	0.0157	CbGeAlD
Sorafenib—Peripheral sensory neuropathy—Doxorubicin—liver cancer	0.00047	0.0181	CcSEcCtD
Sorafenib—Thromboembolism—Epirubicin—liver cancer	0.000456	0.0175	CcSEcCtD
Sorafenib—KDR—embryo—liver cancer	0.000453	0.0147	CbGeAlD
Sorafenib—CSF1R—embryo—liver cancer	0.000442	0.0143	CbGeAlD
Sorafenib—Thromboembolism—Doxorubicin—liver cancer	0.000422	0.0162	CcSEcCtD
Sorafenib—ZAK—liver—liver cancer	0.000422	0.0137	CbGeAlD
Sorafenib—HIPK3—liver—liver cancer	0.000413	0.0134	CbGeAlD
Sorafenib—KIT—embryo—liver cancer	0.000402	0.013	CbGeAlD
Sorafenib—PDGFRB—embryo—liver cancer	0.000392	0.0127	CbGeAlD
Sorafenib—TIE1—liver—liver cancer	0.000386	0.0125	CbGeAlD
Sorafenib—BRAF—liver—liver cancer	0.00037	0.012	CbGeAlD
Sorafenib—EPHX2—liver—liver cancer	0.000354	0.0115	CbGeAlD
Sorafenib—FLT3—liver—liver cancer	0.000351	0.0114	CbGeAlD
Sorafenib—UGT1A9—liver—liver cancer	0.000324	0.0105	CbGeAlD
Sorafenib—Ascites—Epirubicin—liver cancer	0.000319	0.0123	CcSEcCtD
Sorafenib—FLT4—liver—liver cancer	0.000319	0.0103	CbGeAlD
Sorafenib—CDK7—Idarubicin—Epirubicin—liver cancer	0.000315	0.173	CbGdCrCtD
Sorafenib—CDK7—Daunorubicin—Epirubicin—liver cancer	0.000315	0.173	CbGdCrCtD
Sorafenib—CDK7—Doxorubicin—Epirubicin—liver cancer	0.000315	0.173	CbGdCrCtD
Sorafenib—FGFR1—liver—liver cancer	0.000315	0.0102	CbGeAlD
Sorafenib—Aphthous stomatitis—Epirubicin—liver cancer	0.00031	0.0119	CcSEcCtD
Sorafenib—MAP3K7—liver—liver cancer	0.000298	0.00966	CbGeAlD
Sorafenib—Ascites—Doxorubicin—liver cancer	0.000296	0.0114	CcSEcCtD
Sorafenib—CDK7—Epirubicin—Doxorubicin—liver cancer	0.000292	0.16	CbGdCrCtD
Sorafenib—CDK7—Idarubicin—Doxorubicin—liver cancer	0.000292	0.16	CbGdCrCtD
Sorafenib—CDK7—Daunorubicin—Doxorubicin—liver cancer	0.000292	0.16	CbGdCrCtD
Sorafenib—MKNK2—liver—liver cancer	0.000289	0.00936	CbGeAlD
Sorafenib—Embolism venous—Epirubicin—liver cancer	0.000288	0.0111	CcSEcCtD
Sorafenib—Aphthous stomatitis—Doxorubicin—liver cancer	0.000286	0.011	CcSEcCtD
Sorafenib—MKNK1—liver—liver cancer	0.000285	0.00925	CbGeAlD
Sorafenib—Lymphopenia—Epirubicin—liver cancer	0.000284	0.0109	CcSEcCtD
Sorafenib—CYP3A7—liver—liver cancer	0.000269	0.00872	CbGeAlD
Sorafenib—Embolism venous—Doxorubicin—liver cancer	0.000266	0.0102	CcSEcCtD
Sorafenib—Lymphopenia—Doxorubicin—liver cancer	0.000262	0.0101	CcSEcCtD
Sorafenib—Mucosal inflammation—Epirubicin—liver cancer	0.000262	0.0101	CcSEcCtD
Sorafenib—RALBP1—liver—liver cancer	0.000261	0.00846	CbGeAlD
Sorafenib—Hypophosphataemia—Epirubicin—liver cancer	0.00025	0.0096	CcSEcCtD
Sorafenib—FLT1—liver—liver cancer	0.000248	0.00804	CbGeAlD
Sorafenib—RAF1—liver—liver cancer	0.000247	0.008	CbGeAlD
Sorafenib—Mucosal inflammation—Doxorubicin—liver cancer	0.000243	0.00932	CcSEcCtD
Sorafenib—STK10—liver—liver cancer	0.000235	0.00761	CbGeAlD
Sorafenib—PDGFRA—liver—liver cancer	0.000232	0.00754	CbGeAlD
Sorafenib—Hypophosphataemia—Doxorubicin—liver cancer	0.000231	0.00888	CcSEcCtD
Sorafenib—Folliculitis—Epirubicin—liver cancer	0.000231	0.00887	CcSEcCtD
Sorafenib—CYP3A7-CYP3A51P—liver—liver cancer	0.000229	0.00742	CbGeAlD
Sorafenib—Embolism—Epirubicin—liver cancer	0.000226	0.00869	CcSEcCtD
Sorafenib—UGT1A1—liver—liver cancer	0.000222	0.00719	CbGeAlD
Sorafenib—Folliculitis—Doxorubicin—liver cancer	0.000214	0.00821	CcSEcCtD
Sorafenib—KDR—liver—liver cancer	0.00021	0.0068	CbGeAlD
Sorafenib—MAP2K5—liver—liver cancer	0.00021	0.0068	CbGeAlD
Sorafenib—Embolism—Doxorubicin—liver cancer	0.000209	0.00804	CcSEcCtD
Sorafenib—CSF1R—liver—liver cancer	0.000205	0.00664	CbGeAlD
Sorafenib—Pleural effusion—Epirubicin—liver cancer	0.00019	0.00728	CcSEcCtD
Sorafenib—KIT—liver—liver cancer	0.000186	0.00603	CbGeAlD
Sorafenib—PDGFRB—liver—liver cancer	0.000181	0.00588	CbGeAlD
Sorafenib—Dysphonia—Epirubicin—liver cancer	0.000176	0.00678	CcSEcCtD
Sorafenib—Pleural effusion—Doxorubicin—liver cancer	0.000175	0.00674	CcSEcCtD
Sorafenib—Neoplasm malignant—Epirubicin—liver cancer	0.00017	0.00653	CcSEcCtD
Sorafenib—Dysphonia—Doxorubicin—liver cancer	0.000163	0.00627	CcSEcCtD
Sorafenib—Bone disorder—Epirubicin—liver cancer	0.000161	0.00617	CcSEcCtD
Sorafenib—Hypocalcaemia—Epirubicin—liver cancer	0.000159	0.00609	CcSEcCtD
Sorafenib—Glossitis—Epirubicin—liver cancer	0.000158	0.00605	CcSEcCtD
Sorafenib—Neoplasm malignant—Doxorubicin—liver cancer	0.000157	0.00604	CcSEcCtD
Sorafenib—Blood bilirubin increased—Epirubicin—liver cancer	0.000153	0.0059	CcSEcCtD
Sorafenib—Bone disorder—Doxorubicin—liver cancer	0.000149	0.00571	CcSEcCtD
Sorafenib—Hypocalcaemia—Doxorubicin—liver cancer	0.000147	0.00564	CcSEcCtD
Sorafenib—Glossitis—Doxorubicin—liver cancer	0.000146	0.0056	CcSEcCtD
Sorafenib—ABCC4—liver—liver cancer	0.000145	0.00469	CbGeAlD
Sorafenib—Blood bilirubin increased—Doxorubicin—liver cancer	0.000142	0.00546	CcSEcCtD
Sorafenib—Influenza like illness—Epirubicin—liver cancer	0.000141	0.00542	CcSEcCtD
Sorafenib—ABCC2—liver—liver cancer	0.00014	0.00454	CbGeAlD
Sorafenib—Skin exfoliation—Epirubicin—liver cancer	0.000139	0.00532	CcSEcCtD
Sorafenib—Neuropathy—Epirubicin—liver cancer	0.000136	0.00524	CcSEcCtD
Sorafenib—Neoplasm—Epirubicin—liver cancer	0.000131	0.00504	CcSEcCtD
Sorafenib—Mouth ulceration—Epirubicin—liver cancer	0.000131	0.00504	CcSEcCtD
Sorafenib—Influenza like illness—Doxorubicin—liver cancer	0.00013	0.00501	CcSEcCtD
Sorafenib—Skin exfoliation—Doxorubicin—liver cancer	0.000128	0.00493	CcSEcCtD
Sorafenib—Neuropathy—Doxorubicin—liver cancer	0.000126	0.00484	CcSEcCtD
Sorafenib—Neoplasm—Doxorubicin—liver cancer	0.000121	0.00467	CcSEcCtD
Sorafenib—Mouth ulceration—Doxorubicin—liver cancer	0.000121	0.00467	CcSEcCtD
Sorafenib—Hepatic function abnormal—Epirubicin—liver cancer	0.000121	0.00463	CcSEcCtD
Sorafenib—CYP2C19—liver—liver cancer	0.00012	0.0039	CbGeAlD
Sorafenib—Eczema—Epirubicin—liver cancer	0.000117	0.0045	CcSEcCtD
Sorafenib—Hepatic failure—Epirubicin—liver cancer	0.000117	0.0045	CcSEcCtD
Sorafenib—Vismodegib—ALB—liver cancer	0.000116	0.0346	CrCbGaD
Sorafenib—Cardiac failure congestive—Epirubicin—liver cancer	0.000116	0.00446	CcSEcCtD
Sorafenib—Renal failure acute—Epirubicin—liver cancer	0.000114	0.00438	CcSEcCtD
Sorafenib—Dermatitis exfoliative—Epirubicin—liver cancer	0.000112	0.00429	CcSEcCtD
Sorafenib—Hepatic function abnormal—Doxorubicin—liver cancer	0.000112	0.00429	CcSEcCtD
Sorafenib—ABCB1—embryo—liver cancer	0.000109	0.00353	CbGeAlD
Sorafenib—Hepatic failure—Doxorubicin—liver cancer	0.000108	0.00417	CcSEcCtD
Sorafenib—Eczema—Doxorubicin—liver cancer	0.000108	0.00417	CcSEcCtD
Sorafenib—Cardiac failure—Epirubicin—liver cancer	0.000108	0.00415	CcSEcCtD
Sorafenib—Cardiac failure congestive—Doxorubicin—liver cancer	0.000107	0.00413	CcSEcCtD
Sorafenib—Hyponatraemia—Epirubicin—liver cancer	0.000106	0.00406	CcSEcCtD
Sorafenib—Renal failure acute—Doxorubicin—liver cancer	0.000106	0.00406	CcSEcCtD
Sorafenib—Pain in extremity—Epirubicin—liver cancer	0.000105	0.00405	CcSEcCtD
Sorafenib—CYP2C8—liver—liver cancer	0.000105	0.0034	CbGeAlD
Sorafenib—Dermatitis exfoliative—Doxorubicin—liver cancer	0.000103	0.00397	CcSEcCtD
Sorafenib—ABCG2—liver—liver cancer	0.000102	0.00331	CbGeAlD
Sorafenib—Cardiac failure—Doxorubicin—liver cancer	9.99e-05	0.00384	CcSEcCtD
Sorafenib—Mood swings—Epirubicin—liver cancer	9.98e-05	0.00383	CcSEcCtD
Sorafenib—CYP1A2—liver—liver cancer	9.82e-05	0.00318	CbGeAlD
Sorafenib—Dehydration—Epirubicin—liver cancer	9.8e-05	0.00376	CcSEcCtD
Sorafenib—Hyponatraemia—Doxorubicin—liver cancer	9.79e-05	0.00376	CcSEcCtD
Sorafenib—Pain in extremity—Doxorubicin—liver cancer	9.75e-05	0.00375	CcSEcCtD
Sorafenib—Dry skin—Epirubicin—liver cancer	9.66e-05	0.00371	CcSEcCtD
Sorafenib—Abdominal pain upper—Epirubicin—liver cancer	9.62e-05	0.0037	CcSEcCtD
Sorafenib—Hypokalaemia—Epirubicin—liver cancer	9.59e-05	0.00368	CcSEcCtD
Sorafenib—Breast disorder—Epirubicin—liver cancer	9.52e-05	0.00366	CcSEcCtD
Sorafenib—Aspartate aminotransferase increased—Epirubicin—liver cancer	9.49e-05	0.00365	CcSEcCtD
Sorafenib—Toxic epidermal necrolysis—Epirubicin—liver cancer	9.49e-05	0.00365	CcSEcCtD
Sorafenib—CYP3A5—liver—liver cancer	9.47e-05	0.00307	CbGeAlD
Sorafenib—Nasopharyngitis—Epirubicin—liver cancer	9.42e-05	0.00362	CcSEcCtD
Sorafenib—CYP2B6—liver—liver cancer	9.41e-05	0.00305	CbGeAlD
Sorafenib—Gastritis—Epirubicin—liver cancer	9.32e-05	0.00358	CcSEcCtD
Sorafenib—CYP2C9—liver—liver cancer	9.32e-05	0.00302	CbGeAlD
Sorafenib—Alanine aminotransferase increased—Epirubicin—liver cancer	9.29e-05	0.00357	CcSEcCtD
Sorafenib—Mood swings—Doxorubicin—liver cancer	9.24e-05	0.00355	CcSEcCtD
Sorafenib—Dysphagia—Epirubicin—liver cancer	9.11e-05	0.0035	CcSEcCtD
Sorafenib—Dehydration—Doxorubicin—liver cancer	9.07e-05	0.00348	CcSEcCtD
Sorafenib—Dry skin—Doxorubicin—liver cancer	8.94e-05	0.00343	CcSEcCtD
Sorafenib—Pancreatitis—Epirubicin—liver cancer	8.93e-05	0.00343	CcSEcCtD
Sorafenib—Abdominal pain upper—Doxorubicin—liver cancer	8.9e-05	0.00342	CcSEcCtD
Sorafenib—Hypokalaemia—Doxorubicin—liver cancer	8.87e-05	0.00341	CcSEcCtD
Sorafenib—Breast disorder—Doxorubicin—liver cancer	8.81e-05	0.00338	CcSEcCtD
Sorafenib—Toxic epidermal necrolysis—Doxorubicin—liver cancer	8.78e-05	0.00337	CcSEcCtD
Sorafenib—Aspartate aminotransferase increased—Doxorubicin—liver cancer	8.78e-05	0.00337	CcSEcCtD
Sorafenib—Nasopharyngitis—Doxorubicin—liver cancer	8.72e-05	0.00335	CcSEcCtD
Sorafenib—Gastritis—Doxorubicin—liver cancer	8.63e-05	0.00331	CcSEcCtD
Sorafenib—Alanine aminotransferase increased—Doxorubicin—liver cancer	8.6e-05	0.0033	CcSEcCtD
Sorafenib—Neutropenia—Epirubicin—liver cancer	8.52e-05	0.00327	CcSEcCtD
Sorafenib—Dysphagia—Doxorubicin—liver cancer	8.43e-05	0.00324	CcSEcCtD
Sorafenib—Pancreatitis—Doxorubicin—liver cancer	8.26e-05	0.00317	CcSEcCtD
Sorafenib—Weight decreased—Epirubicin—liver cancer	8.24e-05	0.00317	CcSEcCtD
Sorafenib—Pneumonia—Epirubicin—liver cancer	8.17e-05	0.00314	CcSEcCtD
Sorafenib—Infestation NOS—Epirubicin—liver cancer	8.12e-05	0.00312	CcSEcCtD
Sorafenib—Infestation—Epirubicin—liver cancer	8.12e-05	0.00312	CcSEcCtD
Sorafenib—Stevens-Johnson syndrome—Epirubicin—liver cancer	8.05e-05	0.00309	CcSEcCtD
Sorafenib—Renal failure—Epirubicin—liver cancer	7.98e-05	0.00307	CcSEcCtD
Sorafenib—Neuropathy peripheral—Epirubicin—liver cancer	7.96e-05	0.00306	CcSEcCtD
Sorafenib—Jaundice—Epirubicin—liver cancer	7.91e-05	0.00304	CcSEcCtD
Sorafenib—Stomatitis—Epirubicin—liver cancer	7.91e-05	0.00304	CcSEcCtD
Sorafenib—Neutropenia—Doxorubicin—liver cancer	7.88e-05	0.00303	CcSEcCtD
Sorafenib—Hepatobiliary disease—Epirubicin—liver cancer	7.68e-05	0.00295	CcSEcCtD
Sorafenib—Epistaxis—Epirubicin—liver cancer	7.66e-05	0.00294	CcSEcCtD
Sorafenib—Weight decreased—Doxorubicin—liver cancer	7.62e-05	0.00293	CcSEcCtD
Sorafenib—Pneumonia—Doxorubicin—liver cancer	7.56e-05	0.0029	CcSEcCtD
Sorafenib—Infestation—Doxorubicin—liver cancer	7.51e-05	0.00289	CcSEcCtD
Sorafenib—Infestation NOS—Doxorubicin—liver cancer	7.51e-05	0.00289	CcSEcCtD
Sorafenib—Stevens-Johnson syndrome—Doxorubicin—liver cancer	7.45e-05	0.00286	CcSEcCtD
Sorafenib—Renal failure—Doxorubicin—liver cancer	7.39e-05	0.00284	CcSEcCtD
Sorafenib—Neuropathy peripheral—Doxorubicin—liver cancer	7.36e-05	0.00283	CcSEcCtD
Sorafenib—Haemoglobin—Epirubicin—liver cancer	7.33e-05	0.00281	CcSEcCtD
Sorafenib—Stomatitis—Doxorubicin—liver cancer	7.32e-05	0.00281	CcSEcCtD
Sorafenib—Jaundice—Doxorubicin—liver cancer	7.32e-05	0.00281	CcSEcCtD
Sorafenib—Haemorrhage—Epirubicin—liver cancer	7.29e-05	0.0028	CcSEcCtD
Sorafenib—Urinary tract disorder—Epirubicin—liver cancer	7.2e-05	0.00277	CcSEcCtD
Sorafenib—Connective tissue disorder—Epirubicin—liver cancer	7.16e-05	0.00275	CcSEcCtD
Sorafenib—Urethral disorder—Epirubicin—liver cancer	7.15e-05	0.00275	CcSEcCtD
Sorafenib—CYP3A4—liver—liver cancer	7.11e-05	0.0023	CbGeAlD
Sorafenib—Hepatobiliary disease—Doxorubicin—liver cancer	7.11e-05	0.00273	CcSEcCtD
Sorafenib—Epistaxis—Doxorubicin—liver cancer	7.09e-05	0.00272	CcSEcCtD
Sorafenib—CYP2D6—liver—liver cancer	6.99e-05	0.00227	CbGeAlD
Sorafenib—Erythema multiforme—Epirubicin—liver cancer	6.89e-05	0.00265	CcSEcCtD
Sorafenib—Tinnitus—Epirubicin—liver cancer	6.8e-05	0.00261	CcSEcCtD
Sorafenib—Haemoglobin—Doxorubicin—liver cancer	6.78e-05	0.0026	CcSEcCtD
Sorafenib—Flushing—Epirubicin—liver cancer	6.76e-05	0.0026	CcSEcCtD
Sorafenib—Cardiac disorder—Epirubicin—liver cancer	6.76e-05	0.0026	CcSEcCtD
Sorafenib—Haemorrhage—Doxorubicin—liver cancer	6.74e-05	0.00259	CcSEcCtD
Sorafenib—Urinary tract disorder—Doxorubicin—liver cancer	6.66e-05	0.00256	CcSEcCtD
Sorafenib—Connective tissue disorder—Doxorubicin—liver cancer	6.63e-05	0.00255	CcSEcCtD
Sorafenib—Angiopathy—Epirubicin—liver cancer	6.61e-05	0.00254	CcSEcCtD
Sorafenib—Urethral disorder—Doxorubicin—liver cancer	6.61e-05	0.00254	CcSEcCtD
Sorafenib—Immune system disorder—Epirubicin—liver cancer	6.58e-05	0.00253	CcSEcCtD
Sorafenib—Mediastinal disorder—Epirubicin—liver cancer	6.57e-05	0.00252	CcSEcCtD
Sorafenib—Arrhythmia—Epirubicin—liver cancer	6.51e-05	0.0025	CcSEcCtD
Sorafenib—Alopecia—Epirubicin—liver cancer	6.44e-05	0.00247	CcSEcCtD
Sorafenib—Mental disorder—Epirubicin—liver cancer	6.39e-05	0.00245	CcSEcCtD
Sorafenib—Erythema multiforme—Doxorubicin—liver cancer	6.38e-05	0.00245	CcSEcCtD
Sorafenib—Erythema—Epirubicin—liver cancer	6.35e-05	0.00244	CcSEcCtD
Sorafenib—Malnutrition—Epirubicin—liver cancer	6.35e-05	0.00244	CcSEcCtD
Sorafenib—Tinnitus—Doxorubicin—liver cancer	6.29e-05	0.00242	CcSEcCtD
Sorafenib—Flushing—Doxorubicin—liver cancer	6.26e-05	0.0024	CcSEcCtD
Sorafenib—Cardiac disorder—Doxorubicin—liver cancer	6.26e-05	0.0024	CcSEcCtD
Sorafenib—Dysgeusia—Epirubicin—liver cancer	6.21e-05	0.00239	CcSEcCtD
Sorafenib—Angiopathy—Doxorubicin—liver cancer	6.12e-05	0.00235	CcSEcCtD
Sorafenib—Muscle spasms—Epirubicin—liver cancer	6.1e-05	0.00234	CcSEcCtD
Sorafenib—Immune system disorder—Doxorubicin—liver cancer	6.09e-05	0.00234	CcSEcCtD
Sorafenib—Mediastinal disorder—Doxorubicin—liver cancer	6.08e-05	0.00234	CcSEcCtD
Sorafenib—Arrhythmia—Doxorubicin—liver cancer	6.02e-05	0.00231	CcSEcCtD
Sorafenib—Alopecia—Doxorubicin—liver cancer	5.96e-05	0.00229	CcSEcCtD
Sorafenib—Mental disorder—Doxorubicin—liver cancer	5.91e-05	0.00227	CcSEcCtD
Sorafenib—Erythema—Doxorubicin—liver cancer	5.87e-05	0.00226	CcSEcCtD
Sorafenib—Malnutrition—Doxorubicin—liver cancer	5.87e-05	0.00226	CcSEcCtD
Sorafenib—Anaemia—Epirubicin—liver cancer	5.86e-05	0.00225	CcSEcCtD
Sorafenib—Dysgeusia—Doxorubicin—liver cancer	5.75e-05	0.00221	CcSEcCtD
Sorafenib—Syncope—Epirubicin—liver cancer	5.69e-05	0.00219	CcSEcCtD
Sorafenib—Leukopenia—Epirubicin—liver cancer	5.68e-05	0.00218	CcSEcCtD
Sorafenib—Muscle spasms—Doxorubicin—liver cancer	5.64e-05	0.00217	CcSEcCtD
Sorafenib—Loss of consciousness—Epirubicin—liver cancer	5.58e-05	0.00214	CcSEcCtD
Sorafenib—Cough—Epirubicin—liver cancer	5.54e-05	0.00213	CcSEcCtD
Sorafenib—Hypertension—Epirubicin—liver cancer	5.48e-05	0.0021	CcSEcCtD
Sorafenib—Anaemia—Doxorubicin—liver cancer	5.43e-05	0.00208	CcSEcCtD
Sorafenib—Myalgia—Epirubicin—liver cancer	5.4e-05	0.00208	CcSEcCtD
Sorafenib—Arthralgia—Epirubicin—liver cancer	5.4e-05	0.00208	CcSEcCtD
Sorafenib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—liver cancer	5.36e-05	0.00206	CcSEcCtD
Sorafenib—Dry mouth—Epirubicin—liver cancer	5.28e-05	0.00203	CcSEcCtD
Sorafenib—Syncope—Doxorubicin—liver cancer	5.26e-05	0.00202	CcSEcCtD
Sorafenib—Leukopenia—Doxorubicin—liver cancer	5.26e-05	0.00202	CcSEcCtD
Sorafenib—Anaphylactic shock—Epirubicin—liver cancer	5.18e-05	0.00199	CcSEcCtD
Sorafenib—Loss of consciousness—Doxorubicin—liver cancer	5.16e-05	0.00198	CcSEcCtD
Sorafenib—Infection—Epirubicin—liver cancer	5.14e-05	0.00198	CcSEcCtD
Sorafenib—Cough—Doxorubicin—liver cancer	5.12e-05	0.00197	CcSEcCtD
Sorafenib—Shock—Epirubicin—liver cancer	5.09e-05	0.00196	CcSEcCtD
Sorafenib—Nervous system disorder—Epirubicin—liver cancer	5.08e-05	0.00195	CcSEcCtD
Sorafenib—Thrombocytopenia—Epirubicin—liver cancer	5.07e-05	0.00195	CcSEcCtD
Sorafenib—Hypertension—Doxorubicin—liver cancer	5.07e-05	0.00195	CcSEcCtD
Sorafenib—ABCB1—liver—liver cancer	5.03e-05	0.00163	CbGeAlD
Sorafenib—Skin disorder—Epirubicin—liver cancer	5.03e-05	0.00193	CcSEcCtD
Sorafenib—Myalgia—Doxorubicin—liver cancer	5e-05	0.00192	CcSEcCtD
Sorafenib—Arthralgia—Doxorubicin—liver cancer	5e-05	0.00192	CcSEcCtD
Sorafenib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—liver cancer	4.96e-05	0.00191	CcSEcCtD
Sorafenib—Anorexia—Epirubicin—liver cancer	4.94e-05	0.0019	CcSEcCtD
Sorafenib—Dry mouth—Doxorubicin—liver cancer	4.89e-05	0.00188	CcSEcCtD
Sorafenib—Anaphylactic shock—Doxorubicin—liver cancer	4.79e-05	0.00184	CcSEcCtD
Sorafenib—Infection—Doxorubicin—liver cancer	4.76e-05	0.00183	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Epirubicin—liver cancer	4.72e-05	0.00181	CcSEcCtD
Sorafenib—Shock—Doxorubicin—liver cancer	4.71e-05	0.00181	CcSEcCtD
Sorafenib—Nervous system disorder—Doxorubicin—liver cancer	4.7e-05	0.00181	CcSEcCtD
Sorafenib—Thrombocytopenia—Doxorubicin—liver cancer	4.69e-05	0.0018	CcSEcCtD
Sorafenib—Skin disorder—Doxorubicin—liver cancer	4.65e-05	0.00179	CcSEcCtD
Sorafenib—Dyspnoea—Epirubicin—liver cancer	4.62e-05	0.00177	CcSEcCtD
Sorafenib—Anorexia—Doxorubicin—liver cancer	4.57e-05	0.00175	CcSEcCtD
Sorafenib—Dyspepsia—Epirubicin—liver cancer	4.56e-05	0.00175	CcSEcCtD
Sorafenib—Decreased appetite—Epirubicin—liver cancer	4.5e-05	0.00173	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Epirubicin—liver cancer	4.47e-05	0.00172	CcSEcCtD
Sorafenib—Fatigue—Epirubicin—liver cancer	4.46e-05	0.00172	CcSEcCtD
Sorafenib—Pain—Epirubicin—liver cancer	4.43e-05	0.0017	CcSEcCtD
Sorafenib—Constipation—Epirubicin—liver cancer	4.43e-05	0.0017	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Doxorubicin—liver cancer	4.37e-05	0.00168	CcSEcCtD
Sorafenib—Dyspnoea—Doxorubicin—liver cancer	4.27e-05	0.00164	CcSEcCtD
Sorafenib—Gastrointestinal pain—Epirubicin—liver cancer	4.23e-05	0.00163	CcSEcCtD
Sorafenib—Dyspepsia—Doxorubicin—liver cancer	4.22e-05	0.00162	CcSEcCtD
Sorafenib—Decreased appetite—Doxorubicin—liver cancer	4.17e-05	0.0016	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Doxorubicin—liver cancer	4.14e-05	0.00159	CcSEcCtD
Sorafenib—Fatigue—Doxorubicin—liver cancer	4.13e-05	0.00159	CcSEcCtD
Sorafenib—Urticaria—Epirubicin—liver cancer	4.11e-05	0.00158	CcSEcCtD
Sorafenib—Constipation—Doxorubicin—liver cancer	4.1e-05	0.00157	CcSEcCtD
Sorafenib—Pain—Doxorubicin—liver cancer	4.1e-05	0.00157	CcSEcCtD
Sorafenib—Abdominal pain—Epirubicin—liver cancer	4.09e-05	0.00157	CcSEcCtD
Sorafenib—Body temperature increased—Epirubicin—liver cancer	4.09e-05	0.00157	CcSEcCtD
Sorafenib—Gastrointestinal pain—Doxorubicin—liver cancer	3.92e-05	0.00151	CcSEcCtD
Sorafenib—Hypersensitivity—Epirubicin—liver cancer	3.82e-05	0.00147	CcSEcCtD
Sorafenib—Urticaria—Doxorubicin—liver cancer	3.81e-05	0.00146	CcSEcCtD
Sorafenib—Abdominal pain—Doxorubicin—liver cancer	3.79e-05	0.00146	CcSEcCtD
Sorafenib—Body temperature increased—Doxorubicin—liver cancer	3.79e-05	0.00146	CcSEcCtD
Sorafenib—Asthenia—Epirubicin—liver cancer	3.72e-05	0.00143	CcSEcCtD
Sorafenib—Pruritus—Epirubicin—liver cancer	3.66e-05	0.00141	CcSEcCtD
Sorafenib—Diarrhoea—Epirubicin—liver cancer	3.54e-05	0.00136	CcSEcCtD
Sorafenib—Hypersensitivity—Doxorubicin—liver cancer	3.53e-05	0.00136	CcSEcCtD
Sorafenib—Asthenia—Doxorubicin—liver cancer	3.44e-05	0.00132	CcSEcCtD
Sorafenib—Dizziness—Epirubicin—liver cancer	3.42e-05	0.00132	CcSEcCtD
Sorafenib—Pruritus—Doxorubicin—liver cancer	3.39e-05	0.0013	CcSEcCtD
Sorafenib—Vomiting—Epirubicin—liver cancer	3.29e-05	0.00127	CcSEcCtD
Sorafenib—Diarrhoea—Doxorubicin—liver cancer	3.28e-05	0.00126	CcSEcCtD
Sorafenib—Rash—Epirubicin—liver cancer	3.27e-05	0.00125	CcSEcCtD
Sorafenib—Dermatitis—Epirubicin—liver cancer	3.26e-05	0.00125	CcSEcCtD
Sorafenib—Headache—Epirubicin—liver cancer	3.24e-05	0.00125	CcSEcCtD
Sorafenib—Dizziness—Doxorubicin—liver cancer	3.17e-05	0.00122	CcSEcCtD
Sorafenib—Nausea—Epirubicin—liver cancer	3.08e-05	0.00118	CcSEcCtD
Sorafenib—Vomiting—Doxorubicin—liver cancer	3.05e-05	0.00117	CcSEcCtD
Sorafenib—Rash—Doxorubicin—liver cancer	3.02e-05	0.00116	CcSEcCtD
Sorafenib—Dermatitis—Doxorubicin—liver cancer	3.02e-05	0.00116	CcSEcCtD
Sorafenib—Headache—Doxorubicin—liver cancer	3e-05	0.00115	CcSEcCtD
Sorafenib—Nausea—Doxorubicin—liver cancer	2.85e-05	0.00109	CcSEcCtD
Sorafenib—PDGFRA—Disease—IL6—liver cancer	7.7e-07	8.16e-06	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—AKT1—liver cancer	7.7e-07	8.15e-06	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—KRAS—liver cancer	7.7e-07	8.15e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—GOT1—liver cancer	7.69e-07	8.15e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—GGT1—liver cancer	7.69e-07	8.15e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—CCND1—liver cancer	7.69e-07	8.14e-06	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—HRAS—liver cancer	7.68e-07	8.13e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—JUN—liver cancer	7.67e-07	8.12e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling by GPCR—HRAS—liver cancer	7.66e-07	8.11e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—CTNNB1—liver cancer	7.61e-07	8.06e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—MAPK8—liver cancer	7.61e-07	8.06e-06	CbGpPWpGaD
Sorafenib—RAF1—Disease—KRAS—liver cancer	7.6e-07	8.05e-06	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—MYC—liver cancer	7.58e-07	8.03e-06	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—MYC—liver cancer	7.58e-07	8.03e-06	CbGpPWpGaD
Sorafenib—RAF1—Immune System—PIK3CA—liver cancer	7.57e-07	8.01e-06	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—TGFB1—liver cancer	7.56e-07	8.01e-06	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—TGFB1—liver cancer	7.56e-07	8.01e-06	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—PPARG—liver cancer	7.56e-07	8e-06	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—IL6—liver cancer	7.54e-07	7.99e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—CYP1A1—liver cancer	7.54e-07	7.98e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—CDKN1B—liver cancer	7.53e-07	7.97e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—IL6—liver cancer	7.52e-07	7.96e-06	CbGpPWpGaD
Sorafenib—KIT—Disease—AKT1—liver cancer	7.51e-07	7.95e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—GSTM1—liver cancer	7.5e-07	7.94e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—MMP9—liver cancer	7.46e-07	7.9e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—CDKN1A—liver cancer	7.44e-07	7.87e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—GSTM1—liver cancer	7.43e-07	7.87e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—CASP3—liver cancer	7.38e-07	7.82e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—IL2—liver cancer	7.37e-07	7.8e-06	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—IL6—liver cancer	7.35e-07	7.78e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling by GPCR—IL6—liver cancer	7.33e-07	7.76e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—MAPK8—liver cancer	7.26e-07	7.69e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—HRAS—liver cancer	7.25e-07	7.68e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling by GPCR—AKT1—liver cancer	7.24e-07	7.66e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—MTHFR—liver cancer	7.2e-07	7.63e-06	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—MYC—liver cancer	7.2e-07	7.62e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—CCND1—liver cancer	7.19e-07	7.61e-06	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—TGFB1—liver cancer	7.18e-07	7.6e-06	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—MYC—liver cancer	7.18e-07	7.6e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—JUN—liver cancer	7.17e-07	7.59e-06	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—TGFB1—liver cancer	7.16e-07	7.58e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—PIK3CA—liver cancer	7.15e-07	7.57e-06	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—PIK3CA—liver cancer	7.14e-07	7.56e-06	CbGpPWpGaD
Sorafenib—FGFR1—Disease—AKT1—liver cancer	7.13e-07	7.55e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—CTNNB1—liver cancer	7.12e-07	7.53e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	7.11e-07	7.53e-06	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—AKT1—liver cancer	7.11e-07	7.53e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—CYP1A1—liver cancer	7.11e-07	7.52e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—RAF1—liver cancer	7.1e-07	7.51e-06	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—PIK3CA—liver cancer	7.07e-07	7.49e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—PSMA4—liver cancer	7.07e-07	7.49e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—PSMD10—liver cancer	7.07e-07	7.49e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—PPARA—liver cancer	7.07e-07	7.48e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—CYP1A1—liver cancer	7.05e-07	7.46e-06	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—PIK3CD—liver cancer	7.04e-07	7.45e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—MTHFR—liver cancer	7.03e-07	7.44e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—VEGFA—liver cancer	7.03e-07	7.44e-06	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—KRAS—liver cancer	7.01e-07	7.42e-06	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—KRAS—liver cancer	7.01e-07	7.42e-06	CbGpPWpGaD
Sorafenib—RAF1—Immune System—HRAS—liver cancer	7e-07	7.41e-06	CbGpPWpGaD
Sorafenib—RAF1—Disease—PIK3CA—liver cancer	6.99e-07	7.4e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—MMP9—liver cancer	6.98e-07	7.39e-06	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—AKT1—liver cancer	6.96e-07	7.37e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—STAT3—liver cancer	6.96e-07	7.37e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—CDKN1A—liver cancer	6.95e-07	7.36e-06	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—ALB—liver cancer	6.95e-07	7.36e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—IL6—liver cancer	6.94e-07	7.35e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—AKT1—liver cancer	6.94e-07	7.34e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—PIK3CB—liver cancer	6.93e-07	7.34e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—MTOR—liver cancer	6.93e-07	7.34e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—GSTP1—liver cancer	6.91e-07	7.32e-06	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—TP53—liver cancer	6.91e-07	7.31e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—PPARA—liver cancer	6.9e-07	7.3e-06	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—PIK3CD—liver cancer	6.88e-07	7.29e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—GOT2—liver cancer	6.88e-07	7.28e-06	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—TP53—liver cancer	6.84e-07	7.24e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—HMOX1—liver cancer	6.82e-07	7.22e-06	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—ALB—liver cancer	6.79e-07	7.19e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—MAPK8—liver cancer	6.78e-07	7.18e-06	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—AKT1—liver cancer	6.78e-07	7.18e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—PIK3CG—liver cancer	6.78e-07	7.18e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling by GPCR—AKT1—liver cancer	6.77e-07	7.16e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—VEGFA—liver cancer	6.7e-07	7.1e-06	CbGpPWpGaD
Sorafenib—RAF1—Immune System—IL6—liver cancer	6.7e-07	7.09e-06	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—KRAS—liver cancer	6.65e-07	7.04e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—STAT3—liver cancer	6.64e-07	7.03e-06	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—KRAS—liver cancer	6.63e-07	7.02e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—MTHFR—liver cancer	6.63e-07	7.01e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—HRAS—liver cancer	6.61e-07	7e-06	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—HRAS—liver cancer	6.6e-07	6.99e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—MTHFR—liver cancer	6.57e-07	6.95e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—PPARG—liver cancer	6.54e-07	6.93e-06	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—HRAS—liver cancer	6.54e-07	6.93e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—CDKN1B—liver cancer	6.5e-07	6.88e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—PPARA—liver cancer	6.5e-07	6.88e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—CYP2E1—liver cancer	6.47e-07	6.85e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—MYC—liver cancer	6.47e-07	6.85e-06	CbGpPWpGaD
Sorafenib—RAF1—Disease—HRAS—liver cancer	6.46e-07	6.84e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—TGFB1—liver cancer	6.45e-07	6.83e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—PPARA—liver cancer	6.44e-07	6.82e-06	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—PIK3CA—liver cancer	6.44e-07	6.82e-06	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—PIK3CA—liver cancer	6.44e-07	6.82e-06	CbGpPWpGaD
Sorafenib—HTR2C—GPCR downstream signaling—AKT1—liver cancer	6.43e-07	6.81e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—AKT1—liver cancer	6.4e-07	6.78e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—CASP3—liver cancer	6.37e-07	6.75e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—IL2—liver cancer	6.36e-07	6.74e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—GSTM1—liver cancer	6.35e-07	6.72e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	6.35e-07	6.72e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—IL6—liver cancer	6.33e-07	6.7e-06	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—IL6—liver cancer	6.32e-07	6.69e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—VEGFA—liver cancer	6.26e-07	6.63e-06	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—IL6—liver cancer	6.26e-07	6.63e-06	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—TP53—liver cancer	6.23e-07	6.59e-06	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—TP53—liver cancer	6.23e-07	6.59e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—CCND1—liver cancer	6.2e-07	6.57e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—STAT3—liver cancer	6.2e-07	6.57e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—JUN—liver cancer	6.19e-07	6.55e-06	CbGpPWpGaD
Sorafenib—RAF1—Disease—IL6—liver cancer	6.19e-07	6.55e-06	CbGpPWpGaD
Sorafenib—RAF1—Immune System—AKT1—liver cancer	6.18e-07	6.55e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—MYC—liver cancer	6.17e-07	6.53e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—TGFB1—liver cancer	6.15e-07	6.51e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—CTNNB1—liver cancer	6.14e-07	6.5e-06	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—PIK3CB—liver cancer	6.14e-07	6.5e-06	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—PIK3CA—liver cancer	6.11e-07	6.47e-06	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—PIK3CA—liver cancer	6.09e-07	6.45e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—PIK3CG—liver cancer	6.05e-07	6.41e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—CYCS—liver cancer	6.05e-07	6.41e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—MMP9—liver cancer	6.02e-07	6.38e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—CYP1A1—liver cancer	6.02e-07	6.37e-06	CbGpPWpGaD
Sorafenib—UGT1A1—Metabolism—PIK3CA—liver cancer	6.02e-07	6.37e-06	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism—PIK3CA—liver cancer	6.02e-07	6.37e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—CDKN1A—liver cancer	6e-07	6.35e-06	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—PIK3CB—liver cancer	6e-07	6.35e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—KRAS—liver cancer	5.97e-07	6.33e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—PIK3CD—liver cancer	5.96e-07	6.31e-06	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—HRAS—liver cancer	5.96e-07	6.31e-06	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—HRAS—liver cancer	5.96e-07	6.31e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—GOT1—liver cancer	5.94e-07	6.29e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—GGT1—liver cancer	5.94e-07	6.29e-06	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—TP53—liver cancer	5.91e-07	6.26e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—PIK3CG—liver cancer	5.91e-07	6.25e-06	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—TP53—liver cancer	5.89e-07	6.24e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—ALB—liver cancer	5.88e-07	6.23e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—MAPK8—liver cancer	5.86e-07	6.2e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—PPARG—liver cancer	5.84e-07	6.18e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—AKT1—liver cancer	5.84e-07	6.18e-06	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—AKT1—liver cancer	5.83e-07	6.17e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	5.79e-07	6.13e-06	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—AKT1—liver cancer	5.78e-07	6.12e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—MYC—liver cancer	5.76e-07	6.1e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—TGFB1—liver cancer	5.75e-07	6.09e-06	CbGpPWpGaD
Sorafenib—RAF1—Disease—AKT1—liver cancer	5.71e-07	6.04e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—PPARG—liver cancer	5.7e-07	6.04e-06	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—IL6—liver cancer	5.7e-07	6.03e-06	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—IL6—liver cancer	5.7e-07	6.03e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—KRAS—liver cancer	5.7e-07	6.03e-06	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—HRAS—liver cancer	5.65e-07	5.98e-06	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—HRAS—liver cancer	5.64e-07	5.97e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—MTHFR—liver cancer	5.61e-07	5.94e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—PIK3CG—liver cancer	5.57e-07	5.89e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—PIK3CG—liver cancer	5.52e-07	5.84e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—PPARA—liver cancer	5.51e-07	5.83e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—PIK3CA—liver cancer	5.49e-07	5.81e-06	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—IL6—liver cancer	5.41e-07	5.73e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—VEGFA—liver cancer	5.41e-07	5.73e-06	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—IL6—liver cancer	5.4e-07	5.71e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—PPARG—liver cancer	5.37e-07	5.69e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—STAT3—liver cancer	5.35e-07	5.67e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—GSTP1—liver cancer	5.33e-07	5.65e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—PPARG—liver cancer	5.33e-07	5.64e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—KRAS—liver cancer	5.33e-07	5.64e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—PIK3CD—liver cancer	5.32e-07	5.63e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—TP53—liver cancer	5.31e-07	5.62e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—HMOX1—liver cancer	5.26e-07	5.57e-06	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—AKT1—liver cancer	5.26e-07	5.57e-06	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—AKT1—liver cancer	5.26e-07	5.57e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—ALB—liver cancer	5.25e-07	5.56e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—PIK3CA—liver cancer	5.24e-07	5.54e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—PIK3CB—liver cancer	5.2e-07	5.5e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—PIK3CD—liver cancer	5.19e-07	5.5e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—ALB—liver cancer	5.13e-07	5.43e-06	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—PIK3CA—liver cancer	5.1e-07	5.4e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—HRAS—liver cancer	5.08e-07	5.38e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—TP53—liver cancer	5.06e-07	5.36e-06	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—PIK3CA—liver cancer	5.06e-07	5.36e-06	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—AKT1—liver cancer	4.99e-07	5.28e-06	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—AKT1—liver cancer	4.98e-07	5.27e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—MYC—liver cancer	4.98e-07	5.27e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—TGFB1—liver cancer	4.96e-07	5.25e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	4.95e-07	5.24e-06	CbGpPWpGaD
Sorafenib—UGT1A1—Metabolism—AKT1—liver cancer	4.91e-07	5.2e-06	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism—AKT1—liver cancer	4.91e-07	5.2e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—GSTM1—liver cancer	4.9e-07	5.19e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—PIK3CD—liver cancer	4.89e-07	5.18e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—PIK3CA—liver cancer	4.89e-07	5.18e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—IL6—liver cancer	4.86e-07	5.15e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—PIK3CD—liver cancer	4.85e-07	5.14e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—HRAS—liver cancer	4.84e-07	5.13e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—ALB—liver cancer	4.83e-07	5.11e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—ALB—liver cancer	4.79e-07	5.07e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—TP53—liver cancer	4.73e-07	5.01e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—PIK3CG—liver cancer	4.72e-07	4.99e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—CYP1A1—liver cancer	4.65e-07	4.92e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—PIK3CB—liver cancer	4.64e-07	4.91e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—IL6—liver cancer	4.64e-07	4.91e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—KRAS—liver cancer	4.6e-07	4.87e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—PPARG—liver cancer	4.55e-07	4.82e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—HRAS—liver cancer	4.53e-07	4.79e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—PIK3CB—liver cancer	4.53e-07	4.79e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—AKT1—liver cancer	4.48e-07	4.75e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—IL6—liver cancer	4.33e-07	4.59e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—MTHFR—liver cancer	4.33e-07	4.59e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—AKT1—liver cancer	4.28e-07	4.53e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—PIK3CB—liver cancer	4.27e-07	4.52e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—PPARA—liver cancer	4.25e-07	4.5e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—PIK3CB—liver cancer	4.23e-07	4.48e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—PIK3CA—liver cancer	4.22e-07	4.47e-06	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—AKT1—liver cancer	4.17e-07	4.41e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—PIK3CD—liver cancer	4.15e-07	4.39e-06	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—AKT1—liver cancer	4.13e-07	4.38e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—ALB—liver cancer	4.09e-07	4.33e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—TP53—liver cancer	4.09e-07	4.33e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—AKT1—liver cancer	4e-07	4.23e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—HRAS—liver cancer	3.91e-07	4.14e-06	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—PIK3CA—liver cancer	3.74e-07	3.96e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—IL6—liver cancer	3.74e-07	3.96e-06	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—PIK3CA—liver cancer	3.66e-07	3.87e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—PIK3CG—liver cancer	3.64e-07	3.85e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—PIK3CB—liver cancer	3.61e-07	3.83e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—PPARG—liver cancer	3.51e-07	3.72e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—AKT1—liver cancer	3.45e-07	3.65e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—PIK3CD—liver cancer	3.2e-07	3.39e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—PIK3CA—liver cancer	3.17e-07	3.35e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—ALB—liver cancer	3.16e-07	3.34e-06	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—AKT1—liver cancer	3.06e-07	3.24e-06	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—AKT1—liver cancer	2.99e-07	3.16e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—PIK3CA—liver cancer	2.83e-07	2.99e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—PIK3CB—liver cancer	2.79e-07	2.95e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—PIK3CA—liver cancer	2.76e-07	2.92e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—PIK3CA—liver cancer	2.6e-07	2.75e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—AKT1—liver cancer	2.59e-07	2.74e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—PIK3CA—liver cancer	2.58e-07	2.73e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—AKT1—liver cancer	2.31e-07	2.45e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—AKT1—liver cancer	2.25e-07	2.39e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—PIK3CA—liver cancer	2.2e-07	2.33e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—AKT1—liver cancer	2.12e-07	2.25e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—AKT1—liver cancer	2.11e-07	2.23e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—AKT1—liver cancer	1.8e-07	1.91e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—PIK3CA—liver cancer	1.7e-07	1.8e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—AKT1—liver cancer	1.39e-07	1.47e-06	CbGpPWpGaD
